NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME) Q4 Loss And TTM US$81 Million Deficit Test Bullish Profitability Narrative
Zymeworks (ZYME) closed out FY 2025 with Q4 revenue of US$2.5 million and a basic EPS loss of US$0.55, while net income excluding extra items was a loss of US$41.2 million, setting a cautious tone around margins and scale. Over the past four quarters, the company has seen total revenue range from US$2.5 million to US$48.7 million per quarter and basic EPS swing between a small profit of US$0.03 and a loss of US$0.55. This gives investors a wide earnings range to weigh against forecasts and...